Kornimate/medical-research-clean huggingface dataset:
five factor model treatment for borderline personality disorder

Conditions: Borderline Personality Disorder

Summary: the primary purpose of this study is to explore acceptability, feasibility, and preliminary efficacy of a novel cognitive-behavioral treatment for borderline personality disorder (bpd). extant treatments for this condition are intensive, long-term (usually at least one year), and have, understandably, focused on targeting the life-threatening and therapy-interrupting behaviors that often characterize this disorder. bpd, however, is a heterogeneous disorder with diagnostic criteria that can be combined to create over 300 unique symptom presentations (ellis, abrams, \& abrams, 2008); to date, no treatments have been explicitly designed with lower risk presentations of bpd in mind. this is unfortunate, as there is evidence to suggest that the majority of individuals with bpd do not demonstrate the recurrent life-threatening behaviors that warrant intensive, long-term care (trull, useda, conforti, \& doan, 1997; zimmerman \& coryell, 1989). additionally, various studies have shown that the difficulties experienced by individuals with bpd can be understood as manifestations of maladaptive variants of personality traits (e.g., mullins-sweatt et al., 2012). specifically, individuals with bpd demonstrate high levels of neuroticism, and low levels of agreeableness (antagonism) and conscientiousness (disinhibition); these traits may not be universally present across all individuals with bpd, perhaps underscoring the heterogeneity in presentations of this condition.


Eligibility criteria:
inclusion criteria: -diagnosis of borderline personality disorder (bpd) exclusion criteria: * diagnosed psychological conditions that would be better addressed by alternative treatments * previously received more than 5 sessions of cognitive behavioral therapy in the past 5 years * concurrent psychotherapy * medication instability

Keywords: borderline personality disorder treatment cbt five-factor model
shivering and glucose homeostasis

Conditions: Healthy Overweight/Obese

Summary: the purpose of this study is to investigate the effect of prolonged shivering thermogenesis on glucose homeostasis in overweight/obese humans.


Eligibility criteria:
inclusion criteria: * signed informed consent * caucasian * healthy (as determined by dependent physician based on medical questionnaire) * man, or postmenopausal (defined as at least 1year post cessation of menses) woman * aged 40 - 75 years at the start of the study * bmi 27 and 35 kg/m2 * stable dietary habits (no weight loss or gain \>3kg in the past 3 months) exclusion criteria: * - not meeting all inclusion criteria * medication use known to hamper subject's safety during study procedures * co-morbidities to which the intervention or program that may pose as a complicating factor * subjects diagnosed with cardiovascular diseases or cancer * fasting plasma glucose ≥ 7.0 mmol/l * haemoglobin \< 7.8 mmol/l for women, or \< 8.4 mmol/l for men * previously diagnosed with type 2 diabetes * abuse alcohol/drug abuse * subjects who do not want to be informed about unexpected medical findings during the screening/study or do not wish that their physician is informed. * engagement in structured exercise \> 2h per week * participation in another biomedical study within 1 month before the first study * smoking * cold-acclimated, such as takes daily extended cold baths, works in a refrigerated environment, or regular cold-water swimming within 1 month of starting the study

Keywords: type 2 diabetes mellitus shivering thermogenesis skeletal muscle
surveillance for adverse events following pandemic h1n1 immunization

Conditions: Novel Influenza A/H1N1

Summary: influenza vaccines are continuously modified to adjust to the virus antigenic shifts or drifts, and its safety profile may vary. while generally considered safe, influenza vaccines have been associated in the past with increases in cases of guillain-barré syndrome (1976) or with oculorespiratory syndrome (2001). the emergence of a novel strain of h1n1 influenza virus (ph1n1) has prompted health departments worldwide to prepare for mass vaccination campaigns with a new h1n1 pandemic vaccine. following recommendations of the world health organization (who), canada immunized its population with a dose-sparing adjuvanted vaccine. while the adjuvant developed by glaxosmithkline (gsk) has been administered to over 39 000 people, only a few hundred will have been vaccinated with the h1n1 formulation in clinical trials before the mass campaign was launched. with this small number, adverse events occurring at a rate \< 1% will not be detected by these clinical trials. considering that most cases of ph1n1 to date have been relatively mild, it will be imperative to rapidly detect adverse events serious enough to reconsider the use of the vaccine. passive surveillance is collecting notifications of adverse events but the sensitivity of this system is not high and its timeliness is not necessarily optimal. in canada, healthcare workers (hcw) are among those who were offered the new pandemic vaccine in priority. because they were offered the vaccine early in the campaign and because they constitute a well-defined group in good general health, this group of people may be well suited for monitoring the safety of the ph1n1 vaccine. the main objective of this project was to estimate in hcw vaccinated against ph1n1 the frequency of adverse events of sufficient severity to cause work absenteeism or medical consultation. the active surveillance was done in hcw from 3 sites (canadian hospitals) participating in the pandemic influenza research network (pcirn): (1) halifax (nova scotia), (2) quebec city (quebec): 3 hospitals, (3) toronto


Eligibility criteria:
inclusion criteria: * to be a health care worker from one of the three canadian hospitals participating in the public health agency of canada/canadian institutes for health research- influenza research network (pcirn): quebec city, toronto, and halifax. * to have been immunized with the ph1n1 vaccine. * to have an email address. * to be 18 years old and older. exclusion criteria: -

Keywords: h1n1 vaccine safety adverse events health care workers
gene-polymorphisms relating to human subfertility

Conditions: Estradiol Receptor Polymorphism; Progesterone Receptor Polymorphism; IVF; Subfertility

Summary: estradiol is synthesized by granulosa cells of ovaries under control of follicle-stimulating hormone (fsh) and luteinizing hormone (lh). it is known that estradiol plays a crucial role in maturation and fertilization of oocytes. furthermore it is involved in development of secondary female sexual organs, fertility and maintenance of pregnancy. estradiol influences these processes by binding to estradiol receptors (er). they are ligand-depending transcription-factors. in humans there are two subtypes: era and erb, which are synthetized from gene esr1 on chromosome 6 and esr2 on chromosome 14. both subtypes are expressed in the ovary. both genes are polymorph. especially for era subtype several polymorphisms and mutations are known which can be linked to breast cancer, spontaneous abortions, osteoporosis and the point in time of menarche. furthermore some studies have shown a relationship between certain polymorphisms and the risk of infertility associated gynecological malfunctions and the result of ivf treatments. progesterone is a hormone which plays a crucial role in initiation and maintenance of pregnancy. it induces the transformation of the endometrium, which facilitates the implantation of the fertilized oocyte and supports the pregnancy. progesterone acts by binding to its receptor. the gene for this receptor is polymorph within the population, whereas some variants seem to account for implantation failure of embryos. in the investigators study the investigators will analyse the role of erp and prp polymorphisms in the context of ivf treatment. the analyzed genotypes are two polymorphisms of esri, called pvu and xba, as well as a variant of esrii, er2. in the progesterone receptor gene a single nucleotide exchange at position +331 (g-\>a) plays a role. the parameters correlated with are concentrations of estradiol, progesterone and fsh, number of follicles, number of fertilized oocytes and pregnancy rate. the investigators hope to optimize established treatment protocols and to improve the chances of success of ivf treatments depending on the genotype of the patient.


Eligibility criteria:
inclusion criteria: * ivf/ icsi treatment with hormonal stimulation * reproductive age * high response or low response or male subfertility exclusion criteria: * other fertility treatments like iui or timed intercourse
asthma outcomes in children after adenotonsillectomy

Conditions: Obstructive Sleep Apnea

Summary: the aim of the study is to assess the effect of adenotonsillectomy on level of asthma control in preschool children with obstructive sleep apnea.

asthma is the most common chronic disease in children ,in children younger than six years it is difficult to diagnose asthma as pulmonary function tests can not be performed reliably before the age six . wheezing is one of the main symptoms of asthma. young children with multiple trigger wheeze as activities ,laughing and crying are more likely to have asthma compared with episodic (viral) wheeze. the mainstay of asthma control is daily administration of inhaled corticosteroids, long acting beta2 agonists and avoid exposure of asthma triggers as seasonal allergens and environmental pollution particularly tobacco smoke exposure. recent studies have found asthma to be associated with overlapping comorbidities including gastroesophageal reflux,obesity and obstructive sleep apnea.this studies have introduced therapeutic strategies aimed at improving asthma control by management of these coexisting conditions. pathophysiological feature of childhood obstructive sleep apnea is presence of increased airway inflammation promoting of hypertrophy of upper airway adenotonsillar tissues . the latter promotes increased pharyngeal resistance thus predispose the upper airway to episodically collapse and cause fragmented sleep that characterize obstructive sleep apnea. surgically adenotonsillectomy is the first line of therapy in childhood obstructive sleep apnea and has favorable outcomes ,including improvements of respiratory sleep disturbances and in reducing markers of asthma and reduction in the use of asthma therapies.

Eligibility criteria:
inclusion criteria: * preschool children (2_5)years with criteria of bronchial asthma with obstructive sleep apnea regardless sex. exclusion criteria: * patients with other disorders that may cause obstructive sleep apnea as cranio facial syndrome , down syndrome, cerebral palsy ,obesity,sickle cell disease, low birth weight. * any associated medical comorbidity that contraindicates general anesthesia.

Keywords: asthma- obstructive sleep apnea-adenotonsillectomy
malnutrition's role in fall risk

Conditions: Falling Injury; Nutrition Disorder

Summary: falls and falls related injuries are considered one of the most adverse events that a patient can experience. several assessment instruments to assess and mitigate risks for falls have been developed. however, these instruments have not addressed nutritional risk factors. weight loss and low hemoglobin levels are key components of malnutrition. malnutrition in the hospital setting is a significant concern and may play a role as a fall risk factor. the world health organization (who) maintains a global anemia database. who has identified iron deficiency anemia, based on hemoglobin value alone as the most common, wide-spread nutritional deficiency worldwide. anemia is present in 30% of the worlds population including industrialized nations. the consensus statement of the academy of nutrition and dietetics / american society of parenteral and enteral nutrition simply defines adult under-nutrition as a continuum of inadequate intake along with a multitude of other factors. weight loss occurs at multiple points along this continuum. this multiphase retrospective descriptive analysis hypothesizes that degree of weight loss and degree of hgb decline may be fall risk factors.

eat well, fall less is a multiphase retrospective descriptive analysis of single event fallers and repeat fallers. data source: documented falls occurring between october 1, 2010 and october 31, 2012. chart review data on weight loss and decline in hemoglobin levels were collected 12 months, 6 months and 3months and 1 month prior to the first fall along as the most recent value prior to the event. additional data on vitamin d levels and c-reactive protein values will be collected at the 12 month, 6month, and 1 month prior to the first fall statistical analysis using sas version 9.1. a two tailed t-test was performed to evaluate differences in hgb characteristics between single and frequent fallers. one way anova evaluated changes in hgb, c-reactive protein, vitamin d values and weight over time are being collected. two constellations of fallers emerged. those with and those without dementia. the two groups appeared to have different nutrition risk factors. all statistical analysis was done using jmp pro (version 10.0.0, sas institute, inc, cary, nc). statistical significance was set at p \< 0.05

Eligibility criteria:
inclusion criteria: * veteran experienced a fall during a hospitalization between october 1, 2010 and october 31, 2012 * veteran must have at least one documented weight a minimum of 24 months prior to admission exclusion criteria: * adults who suffer from neurological disease or stroke * adults with documented orthopedic fracture in the past 12 months * documented amputation of a lower limb in the past 24 months * blindness * history of volume overload, renal, cardiovascular or other in nature * current alcoholic * it is felt that a co-morbidity exists which makes the individuals weight history inaccurate, such as a recent prosthetic device alteration.
minimally invasive versus open surgery for phc

Conditions: Perihilar Cholangiocarcinoma

Summary: brief summary: this is a multicentric, retrospective, real-world study to investigate the surgical outcomes of minimally invasive surgery compared with open surgery for perihilar cholangiocarcinoma (phc), with the perioperative characteristics and long-term overall survival being compared. we aimed to find out whether the minimally invasive surgery is safe or feasible for phc. and we also want to find out patients with what kind of characteristic can be benefit from the minimally invasive surgery compared with the open approach.


Eligibility criteria:
inclusion criteria: histologically confirmed phc. exclusion criteria: 1. peritoneal seeding or metastasis to the liver, para-aortic lymph nodes, or distant sites; 2. non-adenocarcinoma histology; 3. incomplete clinical data.

Keywords: laparoscopic minimally invasive open resection
improving cancer outcomes through personalized care planning and symptom management.

Conditions: Lung Cancer; Breast Cancer; Gynecologic Cancer

Summary: this study is a case control study conducted with 100 patients with a solid tumor cancer diagnosis (lung, breast, or gynecologic cancer). records of 50 patients who received treatment plans as standard of care will be abstracted for control data. 50 patients undergoing cancer treatment will receive a treatment plan and report symptoms using carevive prompt™.


Eligibility criteria:
inclusion criteria: * all participants must be 18 years of age or older. * subject participants must have a diagnosis of a breast, lung, or gynecologic cancer. * patients must have completed their navigation visit and received a treatment care plan. * subjects must be able to complete on-line surveys using a cell phone, tablet, or computer. * subjects must be starting or receiving treatment. * all participants must be able to understand english. exclusion criteria: * any patient who cannot understand written or spoken english. * any patient without the ability to complete on-line surveys using a cell phone, tablet, or computer. * any prisoner and/or other vulnerable persons as defined by nih (45 cfr 46, subpart b, c and d).
anti-tumor specific immune response in head and neck cancers

Conditions: Head and Neck Squamous Cell Carcinoma

Summary: the purpose is the description of anti-tumor immune responses in general and according to clinical stage and disease free survival (dfs: survival without recurrence (local or distant)) in patients with head \& neck squamous cell carcinoma secondary purposes are: * study of relationship between anti-tumor immune response and qualitative (yes/no) and quantitative (number) presence of circulating tumor cells (ctcs); * study of relationship between qualitative (yes/no) and quantitative (number) presence of ctcs and clinical stage as well as dfs * study of relationship between anti-tumor immune response and clinical stage as well as dfs.


Eligibility criteria:
inclusion criteria: * patient with head \& neck squamous cell carcinoma after extension assessment, regardless of clinical stage (tnm uicc stage i-iv), before any medical or surgical treatment specifically directed against cancer (radiotherapy, surgery, chemotherapy or targeted therapy) * consent to participate to the study, non-opposition * affiliation to social security exclusion criteria: * history of neoplasia, synchronous cancer, auto-immune disease, organ transplantation, chemotherapy * hiv infection * corticotherapy during 15 days before blood sampling
a clinical evaluation on traditional chinese medicine diagnosis and treatment program blocking and reversing hepatitis b-related liver fibrosis - a randomized, controlled, double-blind, multi-center clinical trial

Conditions: Liver Fibrosis; Chronic Hepatitis B

Summary: this research puts liver biopsy as the enrollment screening criteria and the primary efficacy assessment indicators. patients at different developmental stages of hepatitis b related liver fibrosis are respectively diagnosed and treated by traditional chinese medicine to determine optional diagnosis and treatment plan of traditional chinese medicine to screen the advantage-treated population and to establish a treatment program, which can save national medical resources, for clinical application of traditional chinese medicine diagnosis and treatment blocking and reversing hepatitis b-related liver fibrosis. the research can help to build automation pathological analysis and diagnosis systems and non-invasive clinical assessment criteria and models of liver fibrosis which can be applied in clinical. it can also help to realize electronic patient data collection and management, to establish patients management centre and follow-up database. then it will help to improve clinical efficacy of being blocked and reversed chronic hepatitis b related liver fibrosis by chinese medicine diagnosis and treatment program, to reduce the incidence of liver cirrhosis and hepatitis b-related mortality, to prolong patients' survival and improve patients' quality of life, to make clinical efficacy, which is about traditional chinese medicine blocking and revering chronic hepatitis b-related liver fibrosis, increase by 15% or more .


Eligibility criteria:
inclusion criteria: inclusion criteria of chronic hepatitis b related liver fibrosis: 1. age from 18 to 65 years old, male or female; 2. consistent with the diagnosis criteria of chronic hepatitis b; 3. liver fibrosis(liver biopsy) stage f ≥ 3 (ishak), hbv dna ≥ 104 copies / ml (or ≥ 2000 iu / ml) were; 4. tcm syndrome type: blood stasis, blood deficiency with toxic heat retention; 5. not taking over nucleoside antiviral in one year, no drug treatment of liver fibrosis in six months; 6. signed informed consent. exclusion criteria: 1. liver fibrosis(liver biopsy) stage f \<3 (ishak); 2. combined with other severe chronic hepatitis, cirrhosis, liver cancer and other severe or end-stage liver disease; 3. accompanied by uncontrollable heart, kidney, lung, endocrine, blood, metabolic and gastrointestinal serious primary disease; or mental illness; 4. pregnant or lactating women; 5. patients with allergic constitution or allergic to tcm used; 6. not be prescribed medication, poor compliance, incomplete data affecting the efficacy and safety of those judgments; 7. patients unsuitable for this trial in researchers' consideration; 8. co-infection with other viral liver disease.
artificial tears, tear lipids and tear film dynamics

Conditions: Dry Eye

Summary: dry eye disease (ded) is pervasive with some reports estimating over 16 million adults diagnosed in the united states. currently, artificial tears remain an integral part of managing dry eyes and are mainly used for symptomatic relief. recent studies have shown there may be therapeutic benefits with regular use of lipid-based artificial tears to improve the structure of the tear film, which may improve tear film stability and provide relief of symptoms. in this study the investigators propose to compare effects on the tear lipid film and its dynamics between 3 lipid based artificial tears and a widely available non-lipid based artificial tear.

this is a prospective, double-masked, randomized, controlled, parallel-group trial designed to compare the impact of systane complete pf lipid-based artificial tears (the treatment solution under study) on tear lipid layer thickness compared with a non-lipid control solution, refresh relieva pf. secondarily, the study will compare changes in tear lipid layer thickness, lipid layer uniformity, tear film thinning dynamics, and symptoms between the treatment solution, the non-lipid control solution, and 2 other available lipid-based solutions (active comparators: refresh optive mega-3 pf and cvs health lubricant eye drop (pg 0.6%)). the study will include 4 clinic visits, and require 1 week of single-masked run-in with systane ultra pf (an over-the-counter non-lipid-based solution) followed by 3 months of study treatment dosing. all subjects will complete a screening interview, then an in-clinic baseline ocular health examination and study eligibility determination followed by dispensing of the control solution to all subjects for 1 week of run-in. after that week, subjects will be randomized to 1 of the 4 artificial tear solutions and have an in-clinic ocular examination and dispense of the assigned solution to use for 3 months. an in-clinic follow-up examination is completed after 1 month of study solution use, followed by a phone interview at 2 months, and a final in-clinic examination at 3 months post-dispensing.

Eligibility criteria:
inclusion criteria: * best corrected visual acuity of 20/30 or better; * experiencing dry eye symptoms (baseline osdi score \>= 13); exclusion criteria: * currently experiencing active ocular inflammation or infection; * currently using topical eye medication (not including over-the-counter eyedrops); * having systemic health conditions or using prescription medications (including but not limited to isotretinoin derivatives) that could alter tear film physiology; * having a history of severe ocular trauma, ocular surgery, or diabetes; * being pregnant or breast feeding; * being a current contact lens wearer; * currently having a condition or being in a situation which, in the examiner's opinion, may put the subject at significant risk, may confound the study results, or may otherwise significantly interfere with their participation in the study;

Keywords: dry eye tear film lipid layer dynamics tear film stability